<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000545</url>
  </required_header>
  <id_info>
    <org_study_id>SLD-CKD-001</org_study_id>
    <nct_id>NCT01000545</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease</brief_title>
  <acronym>DEFINE</acronym>
  <official_title>The Efficacy and Safety of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corbridge Group Philippines, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Corbridge Group Philippines, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect and safety of Sulodexide in Filipino
      patients with Chronic Kidney Disease (CKD).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>macroalbuminuria and serum creatinine</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1508</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>placebo gelcaps + best medical treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c &lt; 7.0%) and BP control (BP&lt; 130/80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLX 500LRU/day + best medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c &lt; 7.0%) and BP control (BP&lt; 130/80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLX 1000LRU/day + best medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c &lt; 7.0%) and BP control (BP&lt; 130/80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLX 2000LRU/day + best medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c &lt; 7.0%) and BP control (BP&lt; 130/80)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulodexide</intervention_name>
    <description>SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.</description>
    <arm_group_label>SLX 500LRU/day + best medical treatment</arm_group_label>
    <arm_group_label>SLX 1000LRU/day + best medical treatment</arm_group_label>
    <arm_group_label>SLX 2000LRU/day + best medical treatment</arm_group_label>
    <other_name>Vessel Due-F</other_name>
    <other_name>SLX</other_name>
    <other_name>Glycosaminoglycans</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo capsules</intervention_name>
    <description>8 soft-gel capsules per day to be taken orally for 12 months</description>
    <arm_group_label>placebo gelcaps + best medical treatment</arm_group_label>
    <other_name>placebo</other_name>
    <other_name>placebo gelcaps</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  positive 2 of 3 ACR &gt; 300 mg/g or 24h urine protein or albumin collection &gt; 300 mg/d
             in the absence of urinary tract infection

          -  serum creatinine 1.3 - 3 mg/dl in women and 1.5 - 3 mg/dl in men

        Exclusion Criteria:

          -  age of onset of DM \&lt; 18 years

          -  + renal disease like non-DM renal disease

          -  + CV diseases such as UA, MI, CABG

          -  + CVA or TIA within last 6 months

          -  untreated UTI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arlene C Crisostomo, M.D., MSc.</last_name>
    <phone>639189004532</phone>
    <email>arlene_crisostomo_md@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathrina B Imperial</last_name>
    <phone>6324487933</phone>
    <phone_ext>116</phone_ext>
    <email>kaye_imperial2004@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mary Mediatrix Medical Center</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Edgardo Faustino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rizal Private Clinics</name>
      <address>
        <city>Metro Manila</city>
        <state>Rizal</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Child Hospital</name>
      <address>
        <city>Dumaguete City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kenneth Coo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoriano R. Potenciano Medical Center</name>
      <address>
        <city>Mandaluyong City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonietta D Dial, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolitan Medical Center</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Susan Y Gan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manila Adventist Medical Center</name>
      <address>
        <city>Pasay City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gingerlita Samonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elizabeth R Sebastian, MD, FPSN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>October 29, 2009</last_update_submitted>
  <last_update_submitted_qc>October 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mr. German A. Panghulan</name_title>
    <organization>Corbridge Group Philippines, Inc.</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Glycosaminoglycans</keyword>
  <keyword>Sulodexide</keyword>
  <keyword>Macroalbuminuria</keyword>
  <keyword>Safety and Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

